For your patients

Lung Foundation Australia has a range of evidence-based services and resources that will enable your patients to better understand and manage their condition. Our services and resources are designed to support clinical treatment plans and help drive optimal health outcomes.

Latest news

3 March 2021 – Centre of Research Excellence in Pulmonary Fibrosis (CRE-PF) Consensus Statement on COVID-19 Vaccination for Adults Living with Interstitial Lung Disease (ILD)

The CRE-PF COVID-19 Working Group is strongly supportive of the Australian Government rollout of Therapeutic Goods Administration (TGA) approved COVID-19 vaccines.

This includes support of COVID-19 vaccination for adults living with interstitial lung disease who may be immunocompromised. All COVID-19 vaccinations approved for use in Australia are effective in reducing rates of COVID-19-related infection, hospitalisation and risk of severe disease.

People living with interstitial lung disease should speak to their treating healthcare team if they have concerns about their specific health circumstances.